Thoratec investor urges firm to put itself up for sale after "unsatisfactory" growth
This article was originally published in Clinica
Executive Summary
Mechanical heart developer Thoratec should put itself up for auction in order to help it expand its market share, according to a major investor. Oracle Investment Management, which has a 5.2% stake in Thoratec and believed to be the second biggest shareholder, sent a letter to the firm's board concluding that "Thoratec is unable to maximise shareholder value as an independent company".